Results for this period
Full year1 April 2025–31 March 2026Non-consolidated (standalone)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Revenue from pharmaceutical intermediates declined substantially due to lower demand. Revenue from agricultural chemical intermediates and functional intermediates increased due to higher demand and new products, but this did not offset the decline in pharmaceutical intermediates, resulting in lower total revenue. Operating profit was affected by the decline in revenue and higher depreciation expenses. Net income increased due to extraordinary income, including the reversal of provision for litigation losses, the reversal of provision for dismantling and removal costs, and insurance proceeds received.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥6,432 million (YoY -2.9%) |
| Operating profit | ¥489 million (YoY -9.6%) |
| Ordinary income | ¥578 million (YoY -10.3%) |
| Profit attributable to owners of the parent | ¥461 million (YoY +27.0%) |
| Net income per share | ¥353.00 |
| Operating Margin | 7.6 % |
| Equity ratio | End of the current fiscal period 68.6 % / End of previous period 64.9 % |
| Total assets | ¥12,189 million |
| Net assets | ¥8,365 million |
| Cash flows from operating activities | ¥1,698 million |
| Cash flows from investing activities | ¥-618 million |
| Cash flows from financing activities | ¥-558 million |
| Cash and cash equivalents at end of period | ¥933 million |
| Full-year earnings forecast | Net Sales ¥6,500 million (YoY +1.0%) / Operating profit To be disclosed at a later date / Ordinary income To be disclosed at a later date / Net income To be disclosed at a later date |
| Annual Dividend Forecast | ¥90 per share → ¥90 per share（0.0%） |
| Payout ratio | 25.5 |
| Regional sales | Category Export revenue / North America Current fiscal year ¥50 million / Previous period ¥27 million / Change ¥23 million / Europe Current fiscal year ¥410 million / Previous period ¥945 million / Change ¥-535 million / Asia and Other Current fiscal year ¥31 million / Previous period ¥10 million / Change ¥21 million |
| Depreciation and amortization | ¥496 million |
| Impairment loss | ¥303 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Reversal of provision for litigation losses ¥38,450 thousand / Reversal of provision for dismantling and removal costs ¥8,506 thousand / Insurance proceeds received ¥30,400 thousand / Total ¥77,357 thousand / Extraordinary loss Loss on Disposal of Fixed Assets ¥18,817 thousand / Impairment loss ¥303 thousand / Costs related to dismantling and removal ¥2,859 thousand / Total ¥21,981 thousand |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 / Excluded 0 / Company name None (no material changes) |
| Material subsequent events | No applicable matters. |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | None (対象者：Not applicable) |
| Issued Shares at Period-End | 1,373,000 |
| Treasury Shares at Period-End | 66,625 |
| Factors Behind Changes in Business Performance | Revenue from pharmaceutical intermediates declined substantially due to lower demand. Revenue from agricultural chemical intermediates and functional intermediates increased due to higher demand and new products, but this did not offset the decline in pharmaceutical intermediates, resulting in lower total revenue. Operating profit was affected by the decline in revenue and higher depreciation expenses. Net income increased due to extraordinary income, including the reversal of provision for litigation losses, the reversal of provision for dismantling and removal costs, and insurance proceeds received. |
Items this document does not state (5)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue declined due to lower demand for pharmaceutical intermediates, particularly a substantial decrease in exports. Operating profit was affected by the decline in revenue and higher depreciation expenses, although the Company also worked to improve productivity and reduce costs. Net income increased due to the recognition of extraordinary income, including the reversal of provision for litigation losses, the reversal of provision for dismantling and removal costs, and insurance proceeds received. Profit forecasts for the next fiscal year will be disclosed at a later date because the impact of the situation in the Middle East is uncertain and reasonable forecasting is difficult.